NEW YORK, July 14, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Neurotrope, Inc. (NASDAQ:NTRP) who purchased shares between January 7, 2016, and April 28, 2017. The action, which was filed in the U.S. District Court for the Southern District of New York, alleges that the Company violated federal securities laws.
The complaint alleges that throughout the Class Period Neurotrope issued materially false and misleading statements and/or failed to disclose material information concerning the efficacy of its lead product candidate, Bryostatin-1. On May 1, 2017, Neurotrope issued a press release announcing “positive top-line results” of the pivotal Phase 2b trials of Bryostatin-1, noting “improvement in patients with moderate to severe Alzheimer’s disease.” However, the underlying trial data contradicts these representations, as the top-line data relating to the 20 microgram dose of Bryostatin-1 failed to produce results that were statistically significant. In addition, Neurotrope failed to disclose statements regarding the efficacy of the 40 microgram dose with regard to its primary and secondary endpoints. Upon this news, shares of Neurotrope fell from a close of $18.81 on April 28, 2017, to a close of $6.97 per share on May 1, 2017.
Shareholders have until July 17, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sa/neurotrope-inc?wire=3.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com


Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 



